Showing results (711-720 of 785) with videos related to

Sort By:
Pageof 79
Journal of Crohn'S & Colitis|January 13, 2025
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studiesRemo Panaccione, Edouard Louis, Jean-Frederic Colombel, et al.
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Remo Panaccione, Brian G Feagan, et al.
Inflammatory Bowel Diseases|July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 StudyScott D Lee, David T Rubin, William J Sandborn, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meetingTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Inflammatory Bowel Diseases|February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisDavid T Rubin, Silvio Danese, Hiroshi Nakase, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 StudiesRemo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Nature Reviews. Gastroenterology & Hepatology|August 28, 2021
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel diseasePablo A Olivera, Stephane Zuily, Paulo G Kotze, et al.
Human Pathology|May 6, 2019
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancersLindsay Alpert, Lindsay Yassan, Rachel Poon, et al.
Genome Biology|April 18, 2023
Metabolic independence drives gut microbial colonization and resilience in health and diseaseAndrea R Watson, Jessika Füssel, Iva Veseli, et al.
Pageof 79